Investigation of the effects of mir-219-1 gene variants on the development of disease in non-small cell lung cancer patients.
NSCLC
miR-219-1 gene
single-nucleotide polymorphisms
Journal
African health sciences
ISSN: 1729-0503
Titre abrégé: Afr Health Sci
Pays: Uganda
ID NLM: 101149451
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
medline:
25
4
2023
pubmed:
24
4
2023
entrez:
24
04
2023
Statut:
ppublish
Résumé
Various variants of the miR-219-1 gene are one of the first genes associated with NSCLC prognosis in the literature. We aimed to genotype two different variants of the miR-219-1 gene and to investigate to using of the result as a biomarker in the diagnosis and treatment of NSCLC. The patients were chosen according to International NSCLC criteria and genomic DNA was isolated from blood (138 patients and 100 healthy individuals). Then qRT-PCR was applied to determine the rs213210 and rs421446 variants of miR-219-1 gene polymorphisms. Allele and genotype frequencies were compared using Pearson's chi-square and Fisher's exact tests test. We found that TT genotype (p=0,381) in rs213210 compared with CC genotype (p=0,165) and CC genotype (p=0,823) in rs421446 compared with TT genotype (p=0,537) did not show a significantly increased risk of NSCLC. There is no relationship between polymorphisms in miR-219-1 and the outcome of NSCLC. miRNA single nucleotide polymorphisms can be used as genetic biomarkers to predict cancer susceptibility, early diagnosis, and prognosis. Our study has shown that two variants of miR-219-1 were not related to NSCLC in the Turkish population. The reason for this can be differences in ethnicity, regions, and background of population and these differences could lead to various outcomes.
Sections du résumé
Background
UNASSIGNED
Various variants of the miR-219-1 gene are one of the first genes associated with NSCLC prognosis in the literature.
Objectives
UNASSIGNED
We aimed to genotype two different variants of the miR-219-1 gene and to investigate to using of the result as a biomarker in the diagnosis and treatment of NSCLC.
Materials and Methods
UNASSIGNED
The patients were chosen according to International NSCLC criteria and genomic DNA was isolated from blood (138 patients and 100 healthy individuals). Then qRT-PCR was applied to determine the rs213210 and rs421446 variants of miR-219-1 gene polymorphisms. Allele and genotype frequencies were compared using Pearson's chi-square and Fisher's exact tests test.
Results
UNASSIGNED
We found that TT genotype (p=0,381) in rs213210 compared with CC genotype (p=0,165) and CC genotype (p=0,823) in rs421446 compared with TT genotype (p=0,537) did not show a significantly increased risk of NSCLC. There is no relationship between polymorphisms in miR-219-1 and the outcome of NSCLC.
Conclusion
UNASSIGNED
miRNA single nucleotide polymorphisms can be used as genetic biomarkers to predict cancer susceptibility, early diagnosis, and prognosis. Our study has shown that two variants of miR-219-1 were not related to NSCLC in the Turkish population. The reason for this can be differences in ethnicity, regions, and background of population and these differences could lead to various outcomes.
Identifiants
pubmed: 37092101
doi: 10.4314/ahs.v22i4.6
pii: jAFHS.v22.i4.pg37
pmc: PMC10117453
doi:
Substances chimiques
MicroRNAs
0
MIRN219 microRNA, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
37-45Informations de copyright
© 2022 Tas SK et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interest.
Références
Onco Targets Ther. 2019 Dec 24;12:11465-11474
pubmed: 31920335
Neuron. 2007 Jun 7;54(5):813-29
pubmed: 17553428
FEBS Lett. 2011 Jul 7;585(13):2087-99
pubmed: 20708002
Front Cell Dev Biol. 2020 Jul 10;8:540
pubmed: 32754587
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Cancer Prev Res (Phila). 2008 Nov;1(6):460-9
pubmed: 19138993
J Mol Diagn. 2017 Sep;19(5):742-754
pubmed: 28732216
Nature. 2012 Feb 15;482(7385):347-55
pubmed: 22337054
Nat Rev Cancer. 2010 Jun;10(6):389-402
pubmed: 20495573
Oncotarget. 2017 Apr 11;8(34):56533-56541
pubmed: 28915609
J Thorac Cardiovasc Surg. 2012 Oct;144(4):794-807
pubmed: 22818121
J Hum Genet. 2017 Jan;62(1):57-65
pubmed: 27488441
Neuron. 2010 Mar 11;65(5):612-26
pubmed: 20223198
Eur J Clin Microbiol Infect Dis. 2008 Feb;27(2):109-14
pubmed: 17973130
Cancer Discov. 2016 Mar;6(3):235-46
pubmed: 26865249
J Clin Microbiol. 2009 Dec;47(12):3881-6
pubmed: 19846633
Dis Markers. 2015;2015:541531
pubmed: 26379361
J Natl Compr Canc Netw. 2021 Dec;19(12):1441-1464
pubmed: 34902832
Nat Rev Drug Discov. 2017 Mar;16(3):203-222
pubmed: 28209991
Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):16-27
pubmed: 26667886
Tumour Biol. 2015 May;36(5):3693-701
pubmed: 25725584
J Clin Oncol. 2013 Mar 10;31(8):1039-49
pubmed: 23401433
Mol Diagn Ther. 2010 Dec 1;14(6):335-42
pubmed: 21275451
Clin Chest Med. 2011 Dec;32(4):703-40
pubmed: 22054881
Cell Physiol Biochem. 2015;37(3):1002-9
pubmed: 26393913
Leg Med (Tokyo). 2012 Jan;14(1):47-50
pubmed: 22177907
Clin Cancer Res. 2012 Jul 15;18(14):3982-91
pubmed: 22661538
Chest. 2005 Jun;127(6):2119-24
pubmed: 15947329
Yonsei Med J. 2010 Jan;51(1):104-10
pubmed: 20046522
Genes Dev. 2018 Jul 1;32(13-14):868-902
pubmed: 29945886
Dig Dis Sci. 2010 Aug;55(8):2288-93
pubmed: 19834808
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8
pubmed: 18663219
Int J Biol Sci. 2020 Jul 19;16(14):2628-2647
pubmed: 32792861